Sang Joon Park

Sang Joon Park

Auto-generated profile, based on publicly available information

Sang Joon Park

Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University Hospital Seoul, Yongsan-gu, Korea (the Republic of)

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2022 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
HKHye Jeong Kim
Hye Jeong Kim
SPSang Joon Park
Sang Joon Park
HPHyeong Kyu Park
Hyeong Kyu Park
DBDong Won Byun
Dong Won Byun
KSKyoil Suh
Kyoil Suh
MYMyung Hi Yoo
Myung Hi Yoo

22 February 2026 in BMJ Open
Verified
Journal Article
Open access
PDF file
SPSang Joon Park
Sang Joon Park
HKHye Jeong Kim
Hye Jeong Kim
MSMihae Seo
Mihae Seo
DBDong Won Byun
Dong Won Byun
KSKyoil Suh
Kyoil Suh
HPHyeong Kyu Park
Hyeong Kyu Park
Objective Type 2 diabetes mellitus has been associated with an increased risk of cognitive decline and dementia, with patients being 1.5–2 times more likely to develop these conditions. While both sodium-glucose co-transporter 2 (SGLT2) inhibitors and thiazolidinediones (TZDs) have shown potential neuroprotective effects in previous studies, their comparative effectiveness for preventing neurodegenerative outcomes has not been established. This study aimed to compare the risk of stroke, dementia and Alzheimer’s disease (AD) between patients treated with SGLT2 inhibitors and those treated with TZDs. Design Multicentre, retrospective, observational, new-user, active-comparator cohort study. Setting Electronic health record-based databases from 11 secondary and tertiary institutions in South Korea from 1 January 2014 to 31 July 2025. The study period began in 2014, following the post-marketing surveillance initiation of SGLT2 inhibitors in Korea (November 2013), to ensure adequate drug availability and clinical adoption. Participants Patients aged 40 years or older who were newly prescribed either SGLT2 inhibitors or TZDs without prior exposure. Interventions Propensity score matching (1:1) was performed using sex as the primary covariate due to data availability constraints in the Observational Medical Outcomes Partnership Common Data Model framework. The HRs with 95% CIs were measured via Cox regression analysis. Results The study analysed 24 172 matched pairs for stroke outcomes (40 483 person-years in the SGLT2 inhibitor group and 39 363 person-years in the TZD group), 25 111 matched pairs for dementia (41 924 person-years in the SGLT2 inhibitor group and 40 726 person-years in the TZD group) and 25 237 matched pairs for AD (42 139 person-years in the SGLT2 inhibitor group and 40 895 person-years in the TZD group) across 11 participating hospitals. After a 1:1 propensity score matching, the SGLT2 inhibitors showed no significant difference in stroke risk (HR 1.18, 95% CI 0.62 to 2.23, p=0.62), while having significant reductions in dementia risk (HR 0.66, 95% CI 0.45 to 0.98, p=0.04) and AD risk (HR 0.54, 95% CI 0.35 to 0.83, p=0.005). Moreover, these protective effects for neurodegenerative outcomes were shown to be consistent across multiple hospital sites. Conclusions SGLT2 inhibitors are associated with a reduced risk of dementia and AD compared with TZDs in patients aged 40 years or older with type 2 diabetes and have neutral effects on stroke risk. These findings confirm the potential selective neuroprotective benefits of SGLT2 inhibitors for neurodegenerative outcomes, which may inform therapeutic decision-making for diabetic patients at risk of cognitive decline.

26 November 2024 in Journal of the Endocrine Society
Verified
Journal Article
Open access
MYMyung Hi Yoo
Myung Hi Yoo
HKHye Jeong Kim
Hye Jeong Kim
SPSuyeon Park
Suyeon Park
SPSang Joon Park
Sang Joon Park
HPHyeong Kyu Park
Hyeong Kyu Park
KSKyoil Suh
Kyoil Suh
Context: Subclinical hypothyroidism (SCH) is characterized by elevated thyroid-stimulating hormone (TSH) levels and normal free thyroxine (fT4) levels. In upper normal TSH levels, thyrotropin-releasing hormone (TRH) stimulation test proved to be useful in identifying an exaggerated TSH response. Objective: We aimed to evaluate the incidence and predictive ability of basal TSH, anti-thyroid peroxidase antibodies (TPOAb), and anti-thyroglobulin antibodies (TgAb) for exaggerated TRH stimulation test in SCH. Methods: A total of 952 subjects with SCH (TSH 4.01-10.00 mIU/L) found during health checkups were evaluated for TSH response to TRH stimulation testing and autoantibodies. Exaggerated TSH response was defined as ΔTSH (peak serum TSH level after TRH injection minus basal TSH level) of > 25.00 mIU/L. Results: The prevalence of exaggerated TSH responses in SCH was 66% (n = 633). The proportion of exaggerated TSH response tended to increase as basal TSH levels increased (P for trend <.001). Also, the proportion of positive TPOAb or TgAb tended to increase as basal TSH levels increased (P for trend <.05). Analysis of predictive ability of basal TSH, positive TPOAb, or TgAb for exaggerated TRH stimulation test revealed that positive TPOAb or TgAb showed high specificity (> 90%) for positive TRH stimulation test but low sensitivity. Basal TSH showed low sensitivity and specificity. Conclusion: Two-thirds of SCH showed exaggerated TRH stimulation test. Positive TPOAb or TgAb showed high specificity (> 90%) for positive TRH stimulation test but basal serum TSH levels showed low predictability. The TRH stimulation test may be a valuable guide to identify SCH patients with hypothyroid state.

12 September 2024 in JMIR Preprints
Verified
Preprint
Open access
SPSang Joon Park
Sang Joon Park
HKHye Jeong Kim
Hye Jeong Kim
DBDong Won Byun
Dong Won Byun
KSKyoil Suh
Kyoil Suh
HYHyeon-Jong Yang
Hyeon-Jong Yang
HPHyeong Kyu Park
Hyeong Kyu Park
BACKGROUND Dementia, especially Alzheimer's disease (AD), increases significantly with age. Type 2 diabetes mellitus (DM) is associated with a higher risk of cognitive decline and dementia. Emerging evidence suggests that certain antidiabetic medications may affect neurodegenerative outcomes. OBJECTIVE This study aimed to compare the risk of stroke, dementia, and AD between patients treated with sodium-glucose co-transporter 2 (SGLT2) inhibitors and those treated with thiazolidinediones (TZDs). METHODS This multicenter retrospective observational cohort study utilized electronic health records from 12 secondary and tertiary hospitals in South Korea from October 1, 2009, to April 30, 2023. Patients aged 55 years or older who were newly prescribed either SGLT2 inhibitors or TZDs without prior exposure were included. Incidence rates of stroke, dementia, and AD were evaluated using propensity score matching and Cox regression analysis to calculate hazard ratios (HRs). RESULTS The study included 31,998 cases of stroke, 33,942 cases of dementia, and 34,500 cases of AD. Compared to TZDs, the use of SGLT2 inhibitors significantly reduced the risk of stroke (HR 0.6248, 95% CI 0.4154–0.9398, P= .0024), dementia (HR 0.5622, 95% CI 0.4077–0.7751, P=.0004), and AD (HR 0.5556, 95% CI 0.3831–0.8056, P=.0019). CONCLUSIONS SGLT2 inhibitors are associated with a reduced risk of stroke, dementia, and Alzheimer's disease compared to TZDs in patients aged 55 years and older with type 2 diabetes. These findings suggest a potential neuroprotective effect of SGLT2 inhibitors, which may inform therapeutic decision-making for type 2 DM patients at risk for neurodegenerative diseases. Further prospective studies are needed to validate these associations and elucidate the underlying mechanisms. CLINICALTRIAL Not applicable